venBio Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 6
- Investments
- 68
- Portfolio
- 28
- Exits
- 35
venBio General Information
Description
Founded in 2009, VenBio is a venture capital firm based in San Francisco, California. The firm seeks to invest in companies operating in the life science, healthcare, therapeutics and biotechnology sectors.
Contact Information
Website
www.venbio.com
Year Founded
2010
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- 1700 Owens Street
- Suite 595
- San Francisco, CA 94158
- United States
+1 (415) 000-0000
venBio Investments (68)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| ImmPACT Bio | 20-Jan-2022 | Later Stage VC | 00000 | Drug Discovery | Generating Revenue | 0000000 000000 00.0 |
| 000000 00000000000 | 19-Jan-2022 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 00000 0000000 00 |
| 00000000 000000000 | 17-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 0000000 000000 00.0 |
| 000000 00000000000 | 29-Nov-2021 | 00000 00000 | 0000 | Drug Discovery | Startup | 00000 0000000 00 |
| 00000000 | 16-Nov-2021 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 0000000 000000 00.0 |
| 00000 000000000000 | 05-Nov-2021 | 00000 00000 | 0000 | Other Pharmaceuticals and Biotechnology | Stealth | |
| 00000000 | 19-Oct-2021 | 00000 00000 | 0000 | Database Software | Generating Revenue | 00000 0000000 00 |
| 000000 000000 | 22-Sep-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue/Not Profitable | |
| Ventyx Biosciences | 20-Sep-2021 | Early Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 00000 0000000 00 |
| Attralus | 08-Sep-2021 | Early Stage VC | 00000 | Drug Discovery | Clinical Trials - General | 0000000 000000 00.0 |
venBio Exits (35)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| CinCor Pharma | 07-Jan-2022 | IPO | 00000 |
| 00 0000000 | 05-Nov-2021 | 000 | 00000 |
| 000000 00000000000 | 21-Oct-2021 | 000 | 00000 |
| 00000 00000000000 | 10-Sep-2021 | 000000 0000000000 | 0000 |
| 00000000 000000000 | 01-Aug-2021 | 000000000000000000 | 00.00 |
| 000000000 00000000 | 25-Jun-2021 | 000 | 00000 |
| 00000 00000000000 | 22-Apr-2021 | 000 | 0000 |
| 000000 00000000000 | 26-Mar-2021 | 000 | 00000 |
| Pharvaris | 05-Feb-2021 | IPO | 00000 |
| ALX Oncology | 11-Dec-2020 | Public Investment 2nd Offering | 00000 |
venBio Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialvenBio Team (12)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Robert Adelman MD | Managing Partner & Co-Founder | 00 | 0 | 0 | San Francisco, CA |
| Aaron Royston MD | Managing Partner | 00 | 0 | 0 | San Francisco, CA |
| Richard Gaster Ph.D | Managing Partner | 00 | 0 | 0 | San Francisco, CA |
| Yvonne Yamanaka Ph.D | Principal | 0 | 0 | 0 | San Francisco, CA |
| David Pezeshki | Chief Financial Officer | San Francisco, CA |
venBio Co-Investors (161)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Vivo Capital | 15 | 0 | 0 |
|
|
| Cormorant Asset Management | 00 | 0 | 0 |
|
|
| Janus Henderson Investors | 0 | 0 |
|
|
|
| Logos Capital | 0 | 0 | 0 |
|
|
| Novo Holdings | 0 | 0 | 00 |
|
|